PHASE II STUDY OF ADI-PEG 20 IN PATIENTS WITH RELAPSED SENSITIVE OR REFRACTORY SMALL CELL LUNG CANCER

Trial Profile

PHASE II STUDY OF ADI-PEG 20 IN PATIENTS WITH RELAPSED SENSITIVE OR REFRACTORY SMALL CELL LUNG CANCER

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs Pegargiminase (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2012 Additional lead trial centres identified as reported by ClinicalTrials.gov.
    • 25 Oct 2012 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 19 May 2012 Planned number of patients changed from 45 to 48 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top